536 related articles for article (PubMed ID: 26411680)
1. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Holmgaard RB; Zamarin D; Li Y; Gasmi B; Munn DH; Allison JP; Merghoub T; Wolchok JD
Cell Rep; 2015 Oct; 13(2):412-24. PubMed ID: 26411680
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
4. Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer.
Yu J; Wang Y; Yan F; Zhang P; Li H; Zhao H; Yan C; Yan F; Ren X
J Immunol; 2014 Sep; 193(5):2574-86. PubMed ID: 25063873
[TBL] [Abstract][Full Text] [Related]
5. IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.
Munn DH; Sharma MD; Johnson TS; Rodriguez P
Cancer Immunol Immunother; 2017 Aug; 66(8):1049-1058. PubMed ID: 28488123
[TBL] [Abstract][Full Text] [Related]
6. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
7. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.
Jitschin R; Braun M; Büttner M; Dettmer-Wilde K; Bricks J; Berger J; Eckart MJ; Krause SW; Oefner PJ; Le Blanc K; Mackensen A; Mougiakakos D
Blood; 2014 Jul; 124(5):750-60. PubMed ID: 24850760
[TBL] [Abstract][Full Text] [Related]
8. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase, Tregs and cancer.
Munn DH
Curr Med Chem; 2011; 18(15):2240-6. PubMed ID: 21517755
[TBL] [Abstract][Full Text] [Related]
11. Monocytic MDSCs regulate macrophage-mediated xenogenic cytotoxicity.
Maeda A; Eguchi H; Nakahata K; Lo PC; Yamanaka K; Kawamura T; Matsuura R; Sakai R; Asada M; Okuyama H; Miyagawa S
Transpl Immunol; 2015 Oct; 33(2):140-5. PubMed ID: 26209355
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
13. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion.
Zoso A; Mazza EM; Bicciato S; Mandruzzato S; Bronte V; Serafini P; Inverardi L
Eur J Immunol; 2014 Nov; 44(11):3307-19. PubMed ID: 25113564
[TBL] [Abstract][Full Text] [Related]
14. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
16. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
18. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
Munn DH; Mellor AL
Trends Immunol; 2016 Mar; 37(3):193-207. PubMed ID: 26839260
[TBL] [Abstract][Full Text] [Related]
19. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
[TBL] [Abstract][Full Text] [Related]
20. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]